Navigation Links
FDA Approves New Treatment for a Type of Late-Stage Skin Cancer
Date:3/25/2011

SILVER SPRING, Md., March 25, 2011 /PRNewswire-USNewswire/ --The U.S. Food and Drug Administration today approved Yervoy (ipilimumab) to treat patients with late-stage (metastatic) melanoma, the most dangerous type of skin cancer.

(Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO)

Melanoma is the leading cause of death from skin disease. An estimated 68,130 new cases of melanoma were diagnosed in the United States during 2010 and about 8,700 people died from the disease, according to the National Cancer Institute.

"Late-stage melanoma is devastating, with very few treatment options for patients, none of which previously prolonged a patient's life," said Richard Pazdur, M.D., director of the Office of Oncology Drug Products in the FDA's Center for Drug Evaluation and Research. "Yervoy is the first therapy approved by the FDA to clearly demonstrate that patients with metastatic melanoma live longer by taking this treatment."

Yervoy is a monoclonal antibody that blocks a molecule known as cytotoxic T-lymphocyte antigen or CTLA-4. CTLA-4 may play a role in slowing down or turning off the body's immune system, affecting its ability to fight off cancerous cells. Yervoy may work by allowing the body's immune system to recognize, target, and attack cells in melanoma tumors. The drug is administered intravenously.

Yervoy's safety and effectiveness were established in a single international study of 676 patients with melanoma. All patients in the study had stopped responding to other FDA-approved or commonly used treatments for melanoma. In addition, participants had disease that had spread or that could not be surgically removed.

The study was designed to measure overall survival, the length of time from when this treatment started until a patient's death. The randomly assigned patients received Yervoy plus an experimental tumor vaccine called gp100, Yervoy alone, or the vaccine alone.

Those who received the combination of Yervoy plus the vaccine or Yervoy alone lived an average of about 10 months, while those who received only the experimental vaccine lived an average of 6.5 months.

Common side effects that can result from autoimmune reactions associated with Yervoy use include fatigue, diarrhea, skin rash, endocrine deficiencies (gland or hormone), and inflammation of the intestines (colitis). Severe to fatal autoimmune reactions were seen in 12.9 percent of patients treated with Yervoy. When severe side effects occurred, Yervoy was stopped and corticosteroid treatment was started. Not all patients responded to this treatment. Patients who did respond in some cases did not see any improvement for several weeks.

Due to the unusual and severe side effects associated with Yervoy, the therapy is being approved with a Risk Evaluation and Mitigation Strategy to inform health care professionals about these serious risks. A medication guide will also be provided to patients to inform them about the therapy's potential side effects.

Yervoy is marketed by New York City-based Bristol-Myers Squibb.

For more information:

FDA: Office of Oncology Drug Products

http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm091745.htm

FDA: Approved Risk Evaluation and Mitigation Strategies (REMS)

http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm111350.htm

FDA: Approved Drugs: Questions and Answers

http://www.fda.gov/Drugs/ResourcesForYou/Consumers/ucm054420.htm

NCI: Melanoma

http://www.cancer.gov/cancertopics/types/melanoma

CDC: Skin Cancer

http://www.cdc.gov/cancer/skin/

Media Inquiries: Erica Jefferson, 301-796-4988, erica.jefferson@fda.hhs.gov

Consumer Inquiries: 888-INFO-FDA


'/>"/>
SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Approves Zostavax Vaccine to Prevent Shingles in Individuals 50 to 59 Years of Age
2. FDA Approves Gadavist for Central Nervous System Scans
3. U.S. FDA Approves Bayers Gadavist™ (Gadobutrol) Injection for MRI of the Central Nervous System
4. FDA Approves Device to Maintain Blood Flow During Artery Bypass Brain Surgery
5. FDA Approves BENLYSTA® for Lupus in Breakthrough for Millions of Sufferers
6. FDA Approves Revised Alphanate® Labeling to Include Reduced Infectivity of an Experimental Model Agent for vCJD
7. UPDATE: FDA Approves New Drug to Treat Chronic Obstructive Pulmonary Disease
8. FDA Approves New Drug to Treat Chronic Obstructive Pulmonary Disease
9. FDA Approves INTUNIV® (guanfacine) Extended-Release Tablets for Use as Adjunctive Therapy to Stimulants for the Treatment of ADHD in Children and Adolescents
10. FDA Approves Edarbi to Treat High Blood Pressure
11. FDA Approves EDARBI (azilsartan medoxomil) for the Treatment of Hypertension
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)...  Marking its one year anniversary since launching ... risk test, Color Genomics announced a ... impact the most common hereditary cancers affecting both ... analyzes hereditary cancer risks for breast, colorectal, melanoma, ... Color Test is physician ordered and includes genetic ...
(Date:4/28/2016)... Net Sales of $1.90 billion represent an increase of 67.8% ... an increase of 1.2% on an adjusted pro forma, constant ... were $0.52 reported, a decrease of 47.5% from the prior ... the prior year period , The Company increases constant ... Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported ...
(Date:4/28/2016)... April 28, 2016  ValGenesis, Inc., the ... Solutions (VLMS) today announced that a prominent ... sufferers of chronic kidney failure has selected ... their corporate validation process. The global medical ... solution to manage their validation processes electronically. ...
Breaking Medicine Technology:
(Date:4/28/2016)... (PRWEB) , ... April 28, 2016 , ... In 2011, ... work in the emerging field of biomechatronics, technology that marries human physiology with electromechanics. ... Media Lab. He is also the Founder of BionX , a leader in ...
(Date:4/28/2016)... (PRWEB) , ... April 28, 2016 , ... One way ... say anything.” This is unfortunately true. But we toss the baby out with the ... single-page brief provides tips for identifying higher-quality studies and otherwise making better use of ...
(Date:4/28/2016)... Phoenix, AZ (PRWEB) , ... ... ... of the AnzuMedical™ Knowledge Sharing and Collaboration Platform™ , today announced ... The platform will provide efficient access to medical knowledge, educational resources, and ...
(Date:4/28/2016)... NC (PRWEB) , ... April 28, 2016 , ... ... announce it has partnered with Community Oncology Pharmacy Association (COPA) to develop a ... the practice of oncology by introducing an accreditation distinction. ACHC provides a wide ...
(Date:4/28/2016)... ... ... Baich had written poetry dating back to her childhood, but after several years without writing ... on a more spiritual tone. The desire to put the words on paper was very ... file it away. Friends would ask her how she wrote such wonderful poetry and her ...
Breaking Medicine News(10 mins):